erwin-aguilar
Erwin Aguilar, PharmD, MSc, MPH
Associate Professor of Internal Medicine

LSU Health Sciences Center in New Orleans - School of Medicine
New Orleans, Louisiana, USA
Phone: (504) 568-2553
E-mail: eaguil@lsuhsc.edu

Education

1997 MPH, Tulane University School of Public Health, New Orleans, Louisiana
1975 Diploma of Advanced Studies, Institute of Biological Chemistry, University Louis Pasteur Strasbourg, France
1971 MSc, Louisiana State University Health Sciences Center, School of Medicine New Orleans, Louisiana
1967 PharmD, National Autonomous University of Nicaragua, León, Nicaragua

Biography

Erwin Aguilar has conducted numerous clinical trials in nephrology and hypertension and several studies on anemia in chronic kidney disease (CKD) in the elderly, and he has conducted a review of osteoporosis diagnosis and treatment patterns in long-term care (LTC) facilities in the Greater New Orleans Area. He is presently conducting clinical trials on diabetic nephropathy in chronic kidney disease patients, dyslipidemia in high cardiovascular risk subjects, and diabetic with cardiovascular complications. In addition, Dr. Aguilar is an Adjunct Associate Professor of Environmental Health in the Department of Global Environmental Health Sciences of Tulane University School of Public Health in New Orleans.


Research Interest

  • Chronic kidney disease
  • Dyslipidemia
  • Diabetic cardiovascular complications
  • Polypharmacy adverse event in the elderly

Scientific Activities

Professional Experience
Associate Professor of Research of Geriatric Medicine   LSU Health Sciences Center in New Orleans - School of Medicine
Associate Professor of Research of Nephrology and Hypertension
Director of Clinical Research
Adjunct Associate Professor of Environmental Health Tulane University School of Public Health in New Orleans.
Other Activities

Dr. Aguilar is a member of the Academy of Sciences of Nicaragua, the Hispanic American Medical Society of Louisiana, and the New York Academy of Sciences.


Publications

  1. Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral S. Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodialysis International. 2016 Sep 12. P. 1-7 doi: 10.1111/hdi.12487.
  2. Aguilar EA, Barry S, Cefalu C, Cheng L, Stolshek B, Bonafede M, Wilson K, Campbell J, Reske T, Hudson W, Abdo A, Tran N, Paoli C.  Osteoporosis diagnosis and management in Long-Term Care Facility.  The American Journal of the Medical Sciences. 2015; 350(5): 357-363.
  3. Diaz MG, Rusak EJ, Aguilar EA, Bellido CA.  Obesity and hypertension in the Argentinian population compared to the white population of the United States of America.  Current Hypertension Reports.  2014 Jul; 16(7): 438-442.
  4. Aguilar EA, Ashraf H, Fontini M, Ruiz M, Reske TM, Cefalu C.  An analysis of chronic kidney disease risk factors in a Louisiana nursing-home population: A cross‐sectional study.  J La State Med Soc.  2013; 165(5): 260-267.
  5. Jie Liao, Zohreh Soltani, Philip Ebenezer, Angel A. Isidro-Carrión, Rubin Zhang, Arshad Asghar, Erwin Aguilar, Joseph Francis, Xuejiao Hu, León Ferder, and Efrain Reisin. Tesaglitazar, a dual Peroxisome Proliferator Activated Receptor Agonist (PPAR α/γ), improves metabolic abnormalities and reduces renal injury in obese Zucker rats. Nephron Exp Nephrol 2010;114:55-62
  6. Paul Muntner, Asghar Arshad, Stephen A Morse, Dharmendrakumar A Patel, Pronabesh D Manapatra, Efrain Reisin, Erwin A Aguilar, Wei Chen, Sathanur Srinivasan and Gerald S Berenson. End-stage Renal Disease in Young Black Males in a Black-White Population: Longitudinal Analysis of the Bogalusa Heart Study, BMC Nephrol. 2009; Dec 2;10:40
  7. Reisin E, Ebenezer PJ, Liao J, Lee BS, Larroque M, Hu X, Aguilar EA, Morse SA, Francis J. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci. 2009 Oct; 338(4):301-9.
  8. Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E: Leptin and Hypertension in Obesity. Journal of Vascular Health and Risk Management 2006; 2:163-169.
  9. Solomonow M. Reisin E. Aguilar EA. Baratta RV. Best R. D'Ambrosia R. Reciprocating gait orthosis powered with electrical muscle stimulation (RGO II). Part II: Medical evaluation of 70 paraplegic patients. Orthopedics 1997; 20(5):411-418.
  10. Solomonow M. Aguilar EA. Reisin E. Baratta RV. Best R. Coetzee T. D'Ambrosia R. Reciprocating gait orthosis powered with electrical muscle stimulation (RGO II). Part I: Performance evaluation of 70 paraplegic patients. Orthopedics 1997; 20(4):315-324.
  11. Solomonow M. Aguilar EA. Reisin E. Baratta RV. Best R. Coetzee T. D'Ambrosia R. Reciprocating gait orthosis powered with electrical muscle stimulation (RGO II). Part I: Performance evaluation of 70 paraplegic patients. Orthopedics 1997; 20(4):315-324.
  12. Thakur V. Reisin E. Solomonow M. Baratta R. Aguilar EA. Best R. D'Ambrosia R. Solanky T. Accuracy of formula-derived creatinine clearance in paraplegic subjects. Clinical Nephrology 1997; 47:237-42, 1997.
  13. Letson GD. D'Ambrosia RD. Aguilar EA. Wagespack A. Department of Orthopedic Surgery, School of Medicine, Louisiana State University Medical Center, New Orleans, USA. Activity relationships of total hip arthroplasty in patients with osteonecrosis and osteoarthritis. Orthopedics 1996; 19(8):665-668.

Aging Studies and Therapies Flyer